285 related articles for article (PubMed ID: 26681486)
1. Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis.
Papamichael K; Van Stappen T; Vande Casteele N; Gils A; Billiet T; Tops S; Claes K; Van Assche G; Rutgeerts P; Vermeire S; Ferrante M
Clin Gastroenterol Hepatol; 2016 Apr; 14(4):543-9. PubMed ID: 26681486
[TBL] [Abstract][Full Text] [Related]
2. Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis.
Papamichael K; Baert F; Tops S; Assche GV; Rutgeerts P; Vermeire S; Gils A; Ferrante M
J Crohns Colitis; 2017 Jan; 11(1):53-59. PubMed ID: 27402915
[TBL] [Abstract][Full Text] [Related]
3. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab.
Turner D; Griffiths AM; Veerman G; Johanns J; Damaraju L; Blank M; Hyams J
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1460-5. PubMed ID: 23672831
[TBL] [Abstract][Full Text] [Related]
4. Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort.
Bossuyt P; Baert F; D'Heygere F; Nakad A; Reenaers C; Fontaine F; Franchimont D; Dewit O; Van Hootegem P; Vanden Branden S; Lambrecht G; Ferrante M;
Inflamm Bowel Dis; 2019 Jan; 25(1):156-162. PubMed ID: 29920582
[TBL] [Abstract][Full Text] [Related]
5. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
Ungar B; Levy I; Yavne Y; Yavzori M; Picard O; Fudim E; Loebstein R; Chowers Y; Eliakim R; Kopylov U; Ben-Horin S
Clin Gastroenterol Hepatol; 2016 Apr; 14(4):550-557.e2. PubMed ID: 26538204
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis.
Brandse JF; Mathôt RA; van der Kleij D; Rispens T; Ashruf Y; Jansen JM; Rietdijk S; Löwenberg M; Ponsioen CY; Singh S; van den Brink GR; D'Haens GR
Clin Gastroenterol Hepatol; 2016 Feb; 14(2):251-8.e1-2. PubMed ID: 26545802
[TBL] [Abstract][Full Text] [Related]
7. Histological healing after infliximab induction therapy in children with ulcerative colitis.
Wiernicka A; Szymanska S; Cielecka-Kuszyk J; Dadalski M; Kierkus J
World J Gastroenterol; 2015 Oct; 21(37):10654-61. PubMed ID: 26457025
[TBL] [Abstract][Full Text] [Related]
8. Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis.
Vande Casteele N; Jeyarajah J; Jairath V; Feagan BG; Sandborn WJ
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1814-1821.e1. PubMed ID: 30613004
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.
Farkas K; Rutka M; Golovics PA; Végh Z; Lovász BD; Nyári T; Gecse KB; Kolar M; Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Malickova K; Bálint A; Nagy F; Bor R; Milassin Á; Szepes Z; Palatka K; Lakatos PL; Lukas M; Molnár T
J Crohns Colitis; 2016 Nov; 10(11):1273-1278. PubMed ID: 27106537
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.
Hassan EA; Ramadan HK; Ismael AA; Mohamed KF; El-Attar MM; Alhelali I
Saudi J Gastroenterol; 2017; 23(4):238-245. PubMed ID: 28721978
[TBL] [Abstract][Full Text] [Related]
11. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis.
Arias MT; Vande Casteele N; Vermeire S; de Buck van Overstraeten A; Billiet T; Baert F; Wolthuis A; Van Assche G; Noman M; Hoffman I; D'Hoore A; Gils A; Rutgeerts P; Ferrante M
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):531-8. PubMed ID: 25117777
[TBL] [Abstract][Full Text] [Related]
12. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ
Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220
[TBL] [Abstract][Full Text] [Related]
13. Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis.
Papamichael K; Rakowsky S; Rivera C; Cheifetz AS; Osterman MT
Aliment Pharmacol Ther; 2018 Feb; 47(4):478-484. PubMed ID: 29210094
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.
Papamichael K; Rivals-Lerebours O; Billiet T; Vande Casteele N; Gils A; Ferrante M; Van Assche G; Rutgeerts PJ; Mantzaris GJ; Peyrin-Biroulet L; Vermeire S
J Crohns Colitis; 2016 Sep; 10(9):1015-23. PubMed ID: 27022161
[TBL] [Abstract][Full Text] [Related]
15. Optimising infliximab induction dosing for patients with ulcerative colitis.
Dreesen E; Faelens R; Van Assche G; Ferrante M; Vermeire S; Gils A; Bouillon T
Br J Clin Pharmacol; 2019 Apr; 85(4):782-795. PubMed ID: 30634202
[TBL] [Abstract][Full Text] [Related]
16. Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort.
Bálint A; Rutka M; Kolar M; Bortlik M; Duricova D; Hruba V; Lukas M; Mitrova K; Malickova K; Lukas M; Szepes Z; Nagy F; Palatka K; Lovas S; Végh Z; Kürti Z; Csontos Á; Miheller P; Nyári T; Bor R; Milassin Á; Fábián A; Szántó K; Lakatos PL; Molnár T; Farkas K
Expert Opin Biol Ther; 2018 Nov; 18(11):1181-1187. PubMed ID: 30277084
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate serum marker of mucosal healing in ulcerative colitis.
de Bruyn M; Arijs I; Wollants WJ; Machiels K; Van Steen K; Van Assche G; Ferrante M; Rutgeerts P; Vermeire S; Opdenakker G
Inflamm Bowel Dis; 2014 Jul; 20(7):1198-207. PubMed ID: 24871805
[TBL] [Abstract][Full Text] [Related]
18. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
Adedokun OJ; Sandborn WJ; Feagan BG; Rutgeerts P; Xu Z; Marano CW; Johanns J; Zhou H; Davis HM; Cornillie F; Reinisch W
Gastroenterology; 2014 Dec; 147(6):1296-1307.e5. PubMed ID: 25173754
[TBL] [Abstract][Full Text] [Related]
19. [Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission].
Muñoz Villafranca C; Bravo Rodríguez MT; Ortiz de Zárate J; Arreba González P; García Kamiruaga I; Heras Martín JI; Cabezudo Gil P; Orive Cura V
Gastroenterol Hepatol; 2016; 39(7):442-8. PubMed ID: 26948837
[TBL] [Abstract][Full Text] [Related]
20. Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients.
Miyoshi J; Matsuoka K; Inoue N; Hisamatsu T; Ichikawa R; Yajima T; Okamoto S; Naganuma M; Sato T; Kanai T; Ogata H; Iwao Y; Hibi T
J Crohns Colitis; 2013 Dec; 7(12):e609-14. PubMed ID: 23680174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
